GNRH agonists vs antagonists in prostate cancer: How to choose
Many factors play into decision-making process when weighing agents.
Many factors play into decision-making process when weighing agents.
“So, in the MoonRISe-1 study, we’re studying the efficacy of TAR-210 to prevent recurrence within the bladder by inserting the TAR-210 in the bladder every…
Patients receiving PUL experienced improvements of 8.6 and (39.1%) and 10 (46.8%) in IPSS total score.
There were no adverse events, such as penile bruising, swelling, edema, allergy, or penile fracture, observed in patients treated with shockwave therapy plus platelet rich…
“[The] NURE-Combo trial provided insights into the potential value of expanding chemotherapy combinations with immune checkpoint [inhibitors] in muscle-invasive disease,” said Chiara Mercinelli, MD.
Angela B. Smith, MD, MS, highlights key takeaways from the session, “Time Efficiency and Productivity Hacks for the Busy Urologist,” which was presented at the…
“BCG worked well enough that we could give it to patients and it worked pretty well. But having the shortage, I think, has ultimately led…
The addition of 18F-DCFPYL PSMA-PET imaging to multi-parametric MRI was associated with an improvement in the detection of clinically significant prostate cancer in men on…
More patients with nonmetastatic castration-sensitive prostate cancer reached an undetectable PSA level if they received enzalutamide, as a single agent or combined with leuprolide, vs…
“We can all learn and collaborate from each other, that way we can continue to provide really great care for our patients,” says Mary W.…
Treatment with the intravesical gemcitabine delivery system TAR-200 led to complete responses in over 80% of patients with BCG-unresponsive, high-risk non–muscle-invasive bladder cancer, according to…